Synta Pharmaceuticals (United States)

Recent papers from Synta Pharmaceuticals (United States)

1. Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistanceBlood · 2026
2. A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1 -mutated or KMT2A -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).Journal of Clinical Oncology · 2026
3. Final results and correlative analysis of entinostat (E) plus pembrolizumab (P) in patients (Pts) with metastatic melanoma (MM) previously treated with anti–PD-(L)1 therapy (Tx).Journal of Clinical Oncology · 2026
4. A Graphical Framework for Testing Hierarchically Structured Hypothesis FamiliesStatistics in Biopharmaceutical Research · 2026
5. Abstract CT048: A first in human, dose escalation (DE) and biomarker cohort expansion (BCE) of IMT-009 (IMT) in advanced cancer and Phase 1b (Ph1b) combination with fruquintinib (F) in microsatellite stable colorectal cancer (MSS CRC)Cancer Research · 2026
6. Abstract A025: SLC1A1/EAAT3 sustains oncogenic metabolic programs in kidney cancerCancer Research · 2026
7. Comment on “Risk of Pericarditis Recurrence Associated With Rilonacept and NSAID/Colchicine Therapy After Initial Pericarditis Presentation: A Retrospective Real-World Comparative Risk Analysis With TriNetX”American Journal of Therapeutics · 2026
8. Pharmacodynamic Analysis of AGAVE-201 Indicates Changes in CSF-1R–Expressing Cells and Associated Biomarkers Potentially Contributing to Chronic Graft-Versus-Host Disease ResolutionTransplantation and Cellular Therapy · 2026
9. Rilonacept reduces pericarditis recurrence risk: clinical outcomes from the RESONANCE patient registryEuropean Heart Journal · 2025
10. Rilonacept as monotherapy for long-term recurrent pericarditis management: sustained disease control over three yearsEuropean Heart Journal · 2025
11. A phase 1/2 study of revumenib in patients (pts) with advanced colorectal cancer (CRC) and other solid tumors.Journal of Clinical Oncology · 2026
12. Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host DiseaseClinical Pharmacology & Therapeutics · 2025
13. Vixarelimab in Patients With Prurigo NodularisJAMA Dermatology · 2025
14. Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AML2025
15. Patient Experience and Improvement Opportunities in Self-Administered, Large-Volume Subcutaneous Infusions at HomePatient Preference and Adherence · 2025
16. FMEnets: Flow, material, and energy networks for non-ideal plug flow reactor designChemical Engineering Science · 2025
17. Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with a KMT2A translocation in the United StatesJournal of Managed Care & Specialty Pharmacy · 2025
18. Hereditary angioedema plasma proteomics following specific plasma kallikrein inhibition with lanadelumabFrontiers in Immunology · 2025
19. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyBlood · 2025
20. Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myelomaBlood Advances · 2025